title: Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.
abstract: Probes for use in time-resolved fluorescence competitive binding assays at melanocortin receptors based on the parental ligands MSH(4), MSH(7), and NDP-α-MSH were prepared by solid phase synthesis methods, purified, and characterized. The saturation binding of these probes was studied using HEK-293 cells engineered to overexpress the human melanocortin 4 receptor (hMC4R) as well as the human cholecystokinin 2 receptor (hCCK2R). The ratios of non-specific binding to total binding approached unity at high concentrations for each probe. At low probe concentrations, receptor-mediated binding and uptake was discernable, and so probe concentrations were kept as low as possible in determining Kd values. The Eu-DTPA-PEGO-MSH(4) probe exhibited low specific binding relative to non-specific binding, even at low nanomolar concentrations, and was deemed unsuitable for use in competition binding assays. The Eu-DTPA-PEGO probes based on MSH(7) and NDP-α-MSH exhibited Kd values of 27±3.9nM and 4.2±0.48nM, respectively, for binding with hMC4R. These probes were employed in competitive binding assays to characterize the interactions of hMC4R with monovalent and divalent MSH(4), MSH(7), and NDP-α-MSH constructs derived from squalene. Results from assays with both probes reflected only statistical enhancements, suggesting improper ligand spacing on the squalene scaffold for the divalent constructs. The Ki values from competitive binding assays that employed the MSH(7)-based probe were generally lower than the Ki values obtained when the probe based on NDP-α-MSH was employed, which is consistent with the greater potency of the latter probe. The probe based on MSH(7) was also competed with monovalent, divalent, and trivalent MSH(4) constructs that previously demonstrated multivalent binding in competitive binding assays against a variant of the probe based on NDP-α-MSH. Results from these assays confirm multivalent binding, but suggest a more modest increase in avidity for these MSH(4) constructs than was previously reported.
authors.affiliation: Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721-0041, USA.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Alleti
authors.forename: Josef
authors.initials: J
authors.lastname: Vagner
authors.forename: Dilani Chathurika
authors.initials: DC
authors.lastname: Dehigaspitiya
authors.forename: Valerie E
authors.initials: VE
authors.lastname: Moberg
authors.forename: N G R D
authors.initials: NG
authors.lastname: Elshan
authors.forename: Narges K
authors.initials: NK
authors.lastname: Tafreshi
authors.forename: Nabila
authors.initials: N
authors.lastname: Brabez
authors.forename: Craig S
authors.initials: CS
authors.lastname: Weber
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Lynch
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Hruby
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Gillies
authors.forename: David L
authors.initials: DL
authors.lastname: Morse
authors.forename: Eugene A
authors.initials: EA
authors.lastname: Mash
mesh_terms: D001667:Binding, Competitive; D005456:Fluorescent Dyes / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D004369:Pentetic Acid / Q000737:chemistry; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding; D043887:Receptor, Cholecystokinin B / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D044105:Receptor, Melanocortin, Type 4 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D044101:Receptors, Melanocortin / Q000737:chemistry / Q000378:metabolism*; D060327:Solid-Phase Synthesis Techniques
chemical_list: D005456:Fluorescent Dyes; C470072:MC4R protein, human; D010455:Peptides; D043887:Receptor, Cholecystokinin B; D044105:Receptor, Melanocortin, Type 4; D044101:Receptors, Melanocortin; D004369:Pentetic Acid
keywords: 1-(9H-fluoren-9-yl)-3,19-dioxo-2,8,11,14,21-pentaoxa-4,18-diazatricosan-23-oic acid; 1-hydroxybenzotriazole; 19-amino-5-oxo-3,10,13,16-tetraoxa-6-azanonadecan-1-oic acid; 6-chloro-1-hydroxybenzotriazole; 9-fluorenylmethyoxycarbonyl; Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH(2); BSA; Cl-HOBt; Competition binding assays; CuAAC; DCM; DIC; DIEA; DMEM; DMF; DMSO; DTPA; Dulbecco’s Modified Eagle Medium; ESI MS; FT-ICR MS; Fluorescent probes; Fmoc; Fmoc-PEGO; Fourier transform ion cyclotron resonance mass spectrometry; HOBt; HRMS; His-DPhe-Arg-Trp; IC(50); MEM; MSH(4); MSH(7); Melanocortin 4 receptor; Minimum Essential Medium; N,N-dimethylformamide; NDP-α-MSH; PEGO; Saturation binding assays; Ser-Nle-Glu-His-DPhe-Arg-Trp; TBTA; TEAA; TFA; THF; TLC; TRF; Time-resolved fluorescence; bovine serum albumin; copper(I)-catalyzed azide-alkyne cycloaddition; dichloromethane; diethylenetriaminepentaacetic acid; diisopropyl carbodiimide; diisopropylethylamine; dimethyl sulfoxide; electrospray ionization mass spectrometry; hMC4R; half maximal inhibitory concentration; high resolution mass spectroscopy; human melanocortin 4 receptor; tetrahydrofuran; thin-layer chromatography; time-resolved fluorescence; triethylammonium acetate; trifluoroacetic acid; tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine
references.citation: J Org Chem. 2005 Sep 2;70(18):7123-32
references.pmid: 16122231
references.citation: Anal Biochem. 2010 Mar 1;398(1):15-23
references.pmid: 19852924
references.citation: Bioorg Med Chem. 2011 Nov 1;19(21):6474-82
references.pmid: 21940174
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2356-65
references.pmid: 19671749
references.citation: ACS Chem Biol. 2007 Feb 20;2(2):119-27
references.pmid: 17291050
references.citation: Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3
references.pmid: 17448660
references.citation: J Med Chem. 1997 Jul 4;40(14):2133-9
references.pmid: 9216831
references.citation: Chem Soc Rev. 2010 Apr;39(4):1302-15
references.pmid: 20309487
references.citation: J Biol Chem. 1993 Jul 15;268(20):15174-9
references.pmid: 8392067
references.citation: Pharmacol Rev. 1999 Dec;51(4):745-81
references.pmid: 10581329
references.citation: Bioorg Med Chem Lett. 2010 Apr 15;20(8):2489-92
references.pmid: 20304640
references.citation: Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8
references.pmid: 6777774
references.citation: J Med Chem. 1987 Nov;30(11):2126-30
references.pmid: 2822931
references.citation: Bioconjug Chem. 2011 Jul 20;22(7):1270-8
references.pmid: 21639139
references.citation: J Med Chem. 1996 Jan 19;39(2):432-5
references.pmid: 8558511
references.citation: J Med Chem. 2011 Oct 27;54(20):7375-84
references.pmid: 21928837
references.citation: J Org Chem. 2010 Sep 3;75(17):5895-903
references.pmid: 20701315
references.citation: Eur J Med Chem. 2007 Jan;42(1):114-24
references.pmid: 17011671
references.citation: Science. 1981 Aug 28;213(4511):1025-7
references.pmid: 6973820
references.citation: Gen Comp Endocrinol. 1989 Jan;73(1):157-63
references.pmid: 2537778
references.citation: J Protein Chem. 2003 May;22(4):335-44
references.pmid: 13678297
references.citation: Anal Biochem. 2004 Jul 15;330(2):242-50
references.pmid: 15203329
references.citation: Angew Chem Int Ed Engl. 2006 Apr 3;45(15):2348-68
references.pmid: 16557636
references.citation: Angew Chem Int Ed Engl. 1998 Nov 2;37(20):2754-2794
references.pmid: 29711117